

**GOVERNMENT OF PAKISTAN**  
**THE PATENT OFFICE**  
2nd Floor, Kandawala Building,  
M.A. Jinnah Road,  
Karachi

No.2/2/2003-F.Sec.

Dated: **14-12-2006**

To,

The Manager,  
Printing Corporation of Pakistan Press,  
University Road,  
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEK-ENDING 19-8-2006 TO BE PUBLISHED ON 14-12-2006  
IN THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)  
Controller of Patents & Designs  
Ph: 9215488

ENCL:

## NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

	<u>15-8-2006</u>	
970/2006	Khawar Naseer Sargodha, Pakistan	“Designing of an injection for its characteristics and disciplines ”
971/2006	Joint Stock Company Latvia, (Priority 15-8-05 Latvia)	“Pharmaceutical composition on basis of reverse transcriptase inhibitor and meldonium”
972/2006	Bayer CropScience Ag, Germany (Priority 9-9-05 Germany)	“ Use of CNI OD formulations for controlling whitefly”
973/2006	Boehringer Ingelheim International GmbH, Germany (Priority 17-8-05 Germany)	“Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions”
974/2006	GlaxoSmithKline Biologicals s.a., Belgium (Priority 17-8-05 GB)	“ Vaccine”
975/2006	Wyeth, USA (Priority 12-3-02 USA) <b>Divisional</b>	“ Intermediate salts useful in process for making chiral 1,4-disubstituted piperazines”
976/2006	Wyeth, USA (Priority 01-5-02 USA) <b>Divisional</b>	“ Pharmaceutically acceptable salts of bicyclic 6-alkylidene-penems as $\beta$ lactamases inhibitors”
977/2006	Wyeth, USA (Priority 15-10-02 USA) <b>Divisional</b>	“ A Pharmaceutical compositions comprising norepinephrine reuptake modulators for preventing and treating vasomotor symptoms”
978/2006	Wyeth, USA (Priority 25-4-02 USA) <b>Divisional</b>	“Pharmaceutically acceptable salts of [1,4] diazepino[6,7,1-1J] quinoline derivatives as antipsychotic and antiobesity agents”

979/2006	Wyeth, USA (Priority 03-12-01 USA) <b>Divisional</b>	“Pharmaceutically acceptable salts of inhibitors of cytosolic phospholipase A2”
980/2006	Novartis AG, Switzerland (Priority 17-8-05 USA)	“Solid dosage forms of valsartan and amlodipine and method and making the same”
981/2006	ESCO Corporation. USA (Priority 30-8-05 USA)	“ Wear assembly for excavating machines”
	<b><u>16-8-2006</u></b>	
982/2006	Bristol-Myers Squibb Company, USA <b>Divisional</b>	“ Heterocyclic dihydropyrimidin salt compound”
983/2006	Bristol-Myers Squibb Company, USA <b>Divisional</b>	“ Heterocyclic diastereomer compound”
984/2006	1. F. Hoffmann-La Roche AG. Switzerland 2. Agouron Pharmaceuticals, Inc. USA <b>Divisional</b>	“ Novel hydroxamic acid derivatives”
985/2006	1. F. Hoffmann-La Roche AG. Switzerland 2. Agouron Pharmaceuticals, Inc. USA <b>Divisional</b>	“ Novel hydroxamic acid derivatives”
986/2006	Bristol-Myers Squibb co., USA <b>Divisional</b>	“ Heterocyclic dihydropyrimidin enantiomer compound”
987/2006	AstraZeneca AB., Sweden (Priority 21-9-99 GB) <b>Divisional</b>	“ A granule composition comprising a pharmaceutically acceptable salt of 1-[4-[2-(2-hydroxyethoxy) ethyl]-1-piperazyl] dibenzo[b,f][1, 4] thiazepine”
988/2006	AstraZeneca AB., Sweden (Priority 21-12-2002 GB) <b>Divisional</b>	“ Novel salt of (2S)-3-(4-{2-[amino]-2-oxoethoxy} phenyl)-2-ethoxypropanoic acid derivative”

989/2006	Bristol-Myers Squibb co., USA <b>Divisional</b>	“ N-[5-[[[5-alkyl-2-oxazolyl]methyl]Thio]-2-thiazolyl]carboxamide inhibitor of cyclin dependent kinase”
990/2006	Janssen Pharmaceutica N.V. Belgium <b>Divisional</b>	“ Tri-or tetrasubstituted pyrimidine derivative salt having HIV replication inhibiting activity”
991/2006	Janssen Pharmaceutica N.V. Belgium (Priority 13-8-2001 Europe) <b>Divisional</b>	“ HIV replication inhibiting pyrimidine”
992/2006	Bristol-Myers Squibb Company USA (Priority 05-12-2004 USA) <b>Divisional</b>	“ A pharmaceutically acceptable salt of calcitonin gene related peptide receptor antagonist”
993/2006	Janssen Pharmaceutical N.V. Belgium (Priority 13-8-2001 Europe) <b>Divisional</b>	“ A pharmaceutical acceptable addition salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benz onitrile(E)”
994/2006	Merck & Co., Inc., USA (Priority 22-1-2001 USA) <b>Divisional</b>	“A pharmaceutically acceptable salt of nucleoside derivative as inhibitor of RNA-dependent RNA viral polymerase”
995/2006	Janseen Pharmaceutica N.V., Belgium (Priority 27-5-2003 PCT) <b>Divisional</b>	“A pharmaceutically acceptable salt of quinazoline derivative”
996/2006	Bristol-Myers Squibb Company, USA (Priority 17-8-2005 USA)	“ Factor Xa inhibitor formulation and method “
997/2006	Dr. Arfa Yasmin Mrs. Rehana Jafri PCSIR, Karachi, Pakistan	“ A process for preparation of sarsabz “
998/2006	Dr. Arfa Yasmin Mrs. Rehana Jafri PCSIR, Karachi, Pakistan	“ A process for preparation of cotton gro”
999/2006	SmithKline Beecham Biological	“ A protein comprising an antigen for use

	S.a., Belgium (Priority 5-2-1998 UK) <b>Divisional</b>	in the treatment of disease “
1000/2006	Wyeth, USA (Priority 2-11-2000 USA) <b>Divisional</b>	“ Pharmaceutically acceptable salts of 1-aryl-or-1-alkylsulfonyl-heterocycliben zazoles as 5-hydroxytryptamine-6 ligands “
	<b><u>17-8-2006</u></b>	
1001/2006	Buhler AG., Switzerland	“ Method for the manufacture of a partially crystalline polycondensate”
1002/2006	H. Lundbeck A/S., Denmark (Priority 17-8-05 Denmark)	“ Novel 2, 3-dihydroindole compounds”
	<b><u>18-8-2006</u></b>	
1003/2006	AstraZeneca AB, Sweden (Priority 26-2-2002 UK) <b>Divisional</b>	“ Pharmaceutically composition comprising a pharmaceutically-acceptable salt thereof (the “Agent”) of 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-( 3-morpholinopropoxy) quinazoline”
1004/2006	AstraZeneca AB, Sweden (Priority 28-3-2002 UK) <b>Divisional</b>	“ A pharmaceutically acceptable salt of a quinoxaline derivative”
1005/2006	1. Bristol-Myers Squibb Company, and 2. Icagen, Inc. USA <b>Divisional</b>	“ An enantiomer of the compound of formula 1 heterocyclo inhibitors of potassium channel”
1006/2006	1. Bristol-Myers Squibb Company, and 2. Icagen, Inc. USA <b>Divisional</b>	“ A diastereomer of the compound of heterocyclo inhibitor of potassium channel”
1007/2006	1. Bristol-Myers Squibb Company, and 2. Icagen, Inc. USA <b>Divisional</b>	“ A salt of the compound of heterocyclo inhibitor of potassium channel”
1008/2006	1. Bristol-Myers Squibb Company, and	“ A solvate of the compound of heterocyclo inhibitor of potassium

	2. Icagen, Inc. USA <b>Divisional</b>	channel”
	<b><u>19-8-2006</u></b>	
1009/2006	Wyeth, USA (Priority 25-12-2002 USA) <b><u>Divisional</u></b>	“ A pharmaceutically acceptable salt of thieno [3, 2-b] pyridine-6-carbonitriles and thieno[2, 3-b] pyridine-5-carbonitriles as protein kinase inhibitors”
1010/2006	AstraZeneca AB, Sweden (Priority 29-8-2005 Sweden)	“ Novel Compounds”
1011/2006	AstraZeneca AB, Sweden (Priority 29-8-2005 Sweden)	“ Novel Compounds”
1012/2006	AstraZeneca AB, Sweden (Priority 26-8-2005 Sweden)	“ Novel Combination”
1013/2006	Eli Lilly and Company, USA (Priority 10-11-03 GB) <b>Divisional</b>	“ A pharmaceutically acceptable salt of a morpholine compound as norepinephrine reuptake inhibitor”

### APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicated their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

921/2004	Shenzhen SYSCAN Technology co., Limited China	“Improved integrated insert-type bar code reader”  (Class: G11B, 13/08)	139211
		Comprising: (a) a circuit board and a contact image sensor component module electrically connecting each other; (b) a body support for fixedly mounting said circuit board and CIS component module, (c) a roller parallel to said CIS component, (d) first photoelectric sensor for sensing the card entering said insertion slot.	
922/2004	Novartis AG, Switzerland	“Microparticles comprising a somatostatin analogue and to a pharmaceutical composition comprising these”  (Class: A61K, 9/26)	139212
		Comprises, microparticles comprising a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer matrix for a long acting release.	
927/2004	Syngenta Participation, AG, Switzerland	“An emulsifiable concentrate comprising herbicidally active 2-[4[(5-chloro-3-fluoropyridin-2-yloxy)-phenosy]-propionic acid compound and use thereof as pesticide”  (Class: A01N, 43/34)	139213
		Comprising; an oil adjuvant and at least one member selected from the group consisting of herbicides, active 2-[4[(5-chloro-3-fluoropyridin-2-yloxy)-phenoxy] propionic acid and quinoline safeners and its use as pesticide.	

930/2004	Cubic Co., Ltd. Japan	“Water pressure transfer method and water pressure transfer article”	139214
		(Class: B44C, 1/175, B41M 3/12)	
		Comprising; a step of applying an ultraviolet ray hardening resin composite on said print pattern of said transfer film, a step of forcing said article underwater together with said transfer film so as to force said print pattern containing said ultraviolet ray hardening composite onto the surface	
931//2004	Honda Motor Co., Ltd Japan	“Fuel Piping”	139215
		(Class: INT.CL.F02M, 37/00, F16L, 11/04, B62J, 37/00)	
		Comprises a pipe member formed of flexible resin material so as to be capable of blending and a connecting portion provided at the end of the pipe member for connecting the fuel tank and the drive unit.	
133/2005	School of Biological Sciences, Lahore, Pakistan	“ A recombinant nucleic acid encoding a protein exhibiting enhanced activity for milk production“	139216
		(Class: INT.CL. C12N, 15/29)	
		Comprises an isolated or recombinant nucleic acid molecules encoding a protein or polypeptide as well as vectors, host cells and composition comprising the encoded protein, exhibiting an enhanced activity for milk production.	

- 163/2005      1. Mrs. Naseem M. Qadri      “A poly herbal composition for non-insulin dependent  
2. Dr. Zakir-ur-Rehman      diabetes mellitus”  
3. Dr. Husan Afroz  
Rizvi,  
PCSIR, Karachi, Pakistan      (Class: INT.CL. A61P, 7/12)

139217

Comprising of different parts of four indigenous medicinal plants/herbs such as gymnema sulvestra, momordica charantia, engenia jambolana trigonella foenum-graeceum making an effective and natural hypoglycemic drug for the treatment of type II diabetes.

### **SEALING FEES DUE**

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139020	Otsuka Pharmaceutical Co, Ltd. Japan	545/2004
139021	SmithKline Plc., USA	550/2004
139022	Geox S.p.A., Italy	552/2004
139023	Novartis Ag., Switzerland	553/2004

139024	Honda Motor Co., Ltd. Japan	555/2004
139025	SmithKline Beecham corporation., USA	556/2004
139026	Coatex S.A.S., France	557/2004
139027	Novartis AG., Switzerland	558/2004
139028	Wyeth, USA	561/2004
139029	Novartis AG, Switzerland	605/2004
139030	Otsuka Pharmaceutical Co, Ltd. Japan	832/2004
139031	Cipla Limited., India	845/2004

(Mrs. Yasmeen Abbasi)  
Controller of Patents & Designs  
Tel: 9215488